Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07805707

PHASE3

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.

Official title: A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Clinical Efficacy of an mRNA Based Seasonal Influenza Vaccine in Older Adults ≥65 Years of Age

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

54000

Start Date

2026-09-02

Completion Date

2028-06-09

Last Updated

2026-09-18

Healthy Volunteers

Yes

Conditions

Influenza, Human

Interventions

COMBINATION_PRODUCT

mRNA Seasonal Flu vaccine

Single-dose intramuscular administration of the season-adapted investigational mRNA Seasonal Flu vaccine.

COMBINATION_PRODUCT

Licensed Influenza Vaccine

Single-dose intramuscular administration of an age-appropriate and season-adapted licensed influenza vaccine used as the active comparator.

Inclusion Criteria: 1. Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of a caregiver. 2. Written or witnessed (physically or digitally) informed consent obtained from the participant/Legally acceptable representative \[LAR(s)\] of the participant prior to performance of any study-specific procedure. 3. Healthy participants or medically stable patients as established by medical history and clinical examination. Participants with chronic medical conditions with or without specific treatment are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrollment. 4. A male or female participant at least 65 YOA at the time of the study intervention administration. Exclusion Criteria: 1. History of test-confirmed influenza infection within 180 days prior to study intervention administration. 2. Any confirmed or suspected immunosuppressive or immunodeficient condition. HIV-infected individuals may be enrolled if they have been stable on antiretroviral therapy for the past 6 consecutive months, their CD4 cell count is ≥ 200/mm³ and their viral load has been undetectable. 3. Hypersensitivity to latex. 4. History of myocarditis or pericarditis considered causally associated with mRNA vaccine. 5. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s). 6. History of hypersensitivity or allergic reaction to any previous influenza vaccine. 7. History of hypersensitivity or allergic reaction to any previous mRNA vaccine. 8. History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine. 9. Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study 10. Acute or unstable chronic conditions \[clinically significant pulmonary, cardiovascular, hepatic, metabolic/endocrine disorders, renal functional abnormality, or psychiatric conditions\], as determined by medical history and clinical examination. 11. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant, due to participation in the clinical study. 12. Condition that in the judgment of the investigator would make intramuscular injection unsafe. 13. Administration of an influenza vaccine in the period starting 180 days before the study intervention administration or planned administration at any time during the study. 14. Planned administration/administration of any mRNA-based vaccine, live vaccine or adjuvanted protein-based vaccine in the period starting 30 days before the study intervention administration (Day -29 to Day 1) and ending 28 days after the study intervention administration (Day 1 to Day 28) or a non-replicating vaccine in the period starting 15 days before the study intervention administration (Day -14 to Day 1) and ending 14 days after the study intervention administration (Day 1 to Day 14). 15. Use of any investigational or non-registered product (drug, vaccine or invasive medical device in the country of enrollment) other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or their planned use during the study period. 16. Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention (Day -89 to Day 1) or planned administration during the study period. 17. Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study. * Up to 90 days prior to the study intervention administration: * For systemic corticosteroids: prednisone equivalent ≥20 mg/day for \>14 days. Inhaled, intra articular/intra-bursal, and topical steroids are allowed. * Long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication. 18. Administration of antitumoral medication during the period starting 90 days before the study intervention (Day -89 to Day 1) or planned administration during the study period. 19. Administration of any vaccine in a clinical trial investigating an influenza mRNA vaccine in the period starting 1 year before the study intervention administration. 20. Concurrently participating in another clinical study at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). 21. For enrollment in Season 2: Previous participation (i.e., during previous season) in this clinical study. 22. Planned move during the study period that will prohibit participating in the study until study end. 23. Planned leave or holiday of 4 consecutive weeks or more during the influenza season covered by the study, that would prohibit the reporting of ILI cases and attendance to ILI visit. 24. Any study personnel or their immediate dependents, family, or household members.

Locations (163)

GSK Investigational Site

Anniston, Alabama, United States

GSK Investigational Site

Guntersville, Alabama, United States

GSK Investigational Site

Glendale, Arizona, United States

GSK Investigational Site

Mesa, Arizona, United States

GSK Investigational Site

Mesa, Arizona, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Scottsdale, Arizona, United States

GSK Investigational Site

Scottsdale, Arizona, United States

GSK Investigational Site

Sun City, Arizona, United States

GSK Investigational Site

Tempe, Arizona, United States

GSK Investigational Site

Tempe, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Little Rock, Arkansas, United States

GSK Investigational Site

Little Rock, Arkansas, United States

GSK Investigational Site

Dublin, California, United States

GSK Investigational Site

Escondido, California, United States

GSK Investigational Site

Fair Oaks, California, United States

GSK Investigational Site

La Palma, California, United States

GSK Investigational Site

Redding, California, United States

GSK Investigational Site

Riverside, California, United States

GSK Investigational Site

Rolling Hills Estates, California, United States

GSK Investigational Site

San Bernardino, California, United States

GSK Investigational Site

San Diego, California, United States

GSK Investigational Site

Walnut Creek, California, United States

GSK Investigational Site

Aurora, Colorado, United States

GSK Investigational Site

Colorado Springs, Colorado, United States

GSK Investigational Site

Stamford, Connecticut, United States

GSK Investigational Site

Waterbury, Connecticut, United States

GSK Investigational Site

Altamonte Springs, Florida, United States

GSK Investigational Site

Fort Lauderdale, Florida, United States

GSK Investigational Site

Hialeah, Florida, United States

GSK Investigational Site

Hialeah, Florida, United States

GSK Investigational Site

Homestead, Florida, United States

GSK Investigational Site

Lake Mary, Florida, United States

GSK Investigational Site

Lake Worth, Florida, United States

GSK Investigational Site

Maitland, Florida, United States

GSK Investigational Site

Melbourne, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami Lakes, Florida, United States

GSK Investigational Site

Miami Lakes, Florida, United States

GSK Investigational Site

Orlando, Florida, United States

GSK Investigational Site

Orlando, Florida, United States

GSK Investigational Site

Palmetto Bay, Florida, United States

GSK Investigational Site

Port Orange, Florida, United States

GSK Investigational Site

Tamarac, Florida, United States

GSK Investigational Site

Tampa, Florida, United States

GSK Investigational Site

Tampa, Florida, United States

GSK Investigational Site

The Villages, Florida, United States

GSK Investigational Site

The Villages, Florida, United States

GSK Investigational Site

West Palm Beach, Florida, United States

GSK Investigational Site

Albany, Georgia, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Decatur, Georgia, United States

GSK Investigational Site

Marietta, Georgia, United States

GSK Investigational Site

Riverdale, Georgia, United States

GSK Investigational Site

Savannah, Georgia, United States

GSK Investigational Site

Meridian, Idaho, United States

GSK Investigational Site

Chicago, Illinois, United States

GSK Investigational Site

Morton, Illinois, United States

GSK Investigational Site

Peoria, Illinois, United States

GSK Investigational Site

Valparaiso, Indiana, United States

GSK Investigational Site

Kansas City, Kansas, United States

GSK Investigational Site

Lenexa, Kansas, United States

GSK Investigational Site

Lafayette, Louisiana, United States

GSK Investigational Site

Metairie, Louisiana, United States

GSK Investigational Site

New Orleans, Louisiana, United States

GSK Investigational Site

Baltimore, Maryland, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Brookline, Massachusetts, United States

GSK Investigational Site

Garden City, Michigan, United States

GSK Investigational Site

Southfield, Michigan, United States

GSK Investigational Site

Southfield, Michigan, United States

GSK Investigational Site

Gulfport, Mississippi, United States

GSK Investigational Site

Chesterfield, Missouri, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

Elkhorn, Nebraska, United States

GSK Investigational Site

Grand Island, Nebraska, United States

GSK Investigational Site

Norfolk, Nebraska, United States

GSK Investigational Site

Omaha, Nebraska, United States

GSK Investigational Site

Las Vegas, Nevada, United States

GSK Investigational Site

Las Vegas, Nevada, United States

GSK Investigational Site

Warren Township, New Jersey, United States

GSK Investigational Site

Santa Fe, New Mexico, United States

GSK Investigational Site

Hartsdale, New York, United States

GSK Investigational Site

Rochester, New York, United States

GSK Investigational Site

Charlotte, North Carolina, United States

GSK Investigational Site

Denver, North Carolina, United States

And 63 more locations on ClinicalTrials.gov

Clinical Research Directory

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (163)